Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients by Benjamin KA Thomson et al.
RESEARCH ARTICLE Open Access
Evaluation of an electronic warfarin nomogram
for anticoagulation of hemodialysis patients
Benjamin KA Thomson1, Jennifer M MacRae1, Lianne Barnieh1, Jianguo Zhang1, Elizabeth MacKay1,
Megan A Manning1 and Brenda R Hemmelgarn1,2*
Abstract
Background: Warfarin nomograms to guide dosing have been shown to improve control of the international
normalized ratio (INR) in the general outpatient setting. However, the effectiveness of these nomograms in
hemodialysis patients is unknown. We evaluated the effectiveness of anticoagulation using an electronic warfarin
nomogram administered by nurses in outpatient hemodialysis patients, compared to physician directed therapy.
Methods: Hemodialysis patients at any of the six outpatient clinics in Calgary, Alberta, treated with warfarin
anticoagulation were included. Two five-month time periods were compared: prior to and post implementation of
the nomogram. The primary endpoint was adequacy of anticoagulation (proportion of INR measurements within
range ± 0.5 units).
Results: Overall, 67 patients were included in the pre- and 55 in the post-period (with 40 patients in both periods).
Using generalized linear mixed models, the adequacy of INR control was similar in both periods for all range INR
levels: in detail, range INR 1.5 to 2.5 (pre 93.6% (95% CI: 88.6% - 96.5%); post 95.6% (95% CI: 89.4% - 98.3%); p =
0.95); INR 2.0 to 3.0 (pre 82.2% (95% CI: 77.9% - 85.8%); post 77.4% (95% CI: 72.0% - 82.0%); p = 0.20); and, INR 2.5
to 3.5 (pre 84.3% (95% CI: 59.4% - 95.1%); post 66.8% (95% CI: 39.9% - 86.0%); p = 0.29). The mean number of INR
measurements per patient decreased significantly between the pre- (30.5, 95% CI: 27.0 - 34.0) and post- (22.3, 95%
CI: 18.4 - 26.1) (p = 0.003) period. There were 3 bleeding events in each of the periods.
Conclusions: An electronic warfarin anticoagulation nomogram administered by nurses achieved INR control similar
to that of physician directed therapy among hemodialysis patients in an outpatient setting, with a significant
reduction in frequency of testing. Future controlled trials are required to confirm the efficacy of this nomogram.
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Background
Warfarin is commonly indicated as an anticoagulant for
the prevention and treatment of thromboembolic dis-
eases. However, warfarin anticoagulation therapy has
been associated with increased risk of bleeding, particu-
larly when the international normalized ratio (INR) is
not maintained within the range therapeutic window
[1,2]. Hemodialysis patients in particular are reported to
experience a markedly increased risk of both throm-
boembolic and bleeding events, approximately 3 to 10
fold higher than the general population [3-6]. Warfarin
anticoagulation in HD patients is also associated with an
increased risk of stroke, and this risk is even higher
when the INR is not routinely monitored in the HD
unit [7].
Achieving anticoagulation therapy within therapeutic
targets may be more challenging for hemodialysis patients
due to a variety of factors including drug and dietary inter-
actions, comorbid illness, and frequent interventions
requiring reversal of anticoagulant therapy. Compared to
physician guided ordering, the use of self-directed or
nurse/pharmacist-guided nomograms to standardize war-
farin dosing and monitoring have been shown to improve
maintenance of anticoagulation in the therapeutic range,
while limiting adverse events such as bleeding or throm-
boses, among inpatients [8-10], outpatients [11-15], and
for a variety of settings [16-20].
* Correspondence: brenda.hemmelgarn@albertahealthservices.ca
1Department of Medicine, University of Calgary, Calgary, Alberta Canada
Full list of author information is available at the end of the article
Thomson et al. BMC Nephrology 2011, 12:46
http://www.biomedcentral.com/1471-2369/12/46
© 2011 Thomson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Thus, given the effectiveness of warfarin nomograms in
the general outpatient population, we evaluated whether
an electronic warfarin anticoagulation nomogram adminis-
tered by nurses was able to achieve similar effectiveness of
anticoagulation compared to physician directed dosing,
among outpatient hemodialysis patients. We also evalu-
ated the incidence of bleeding and thrombotic events.
Methods
Study Population and Observation Period
All hemodialysis patients receiving stable anticoagulation
therapy with warfarin (regardless of the indication), from
any of the six outpatient hemodialysis clinics in Calgary,
Alberta Canada were included. Patients were identified
from the renal program database [21]. Two five-month
time periods were considered: a pre-period prior to the
implementation of the warfarin nomogram (August 1 -
December 31, 2008), and a post-period, following imple-
mentation of the nomogram (March 1 - July 31, 2009).
Eligible patients were included in the pre-period and/or in
the post-period.
Warfarin Nomogram
Warfarin dosing and frequency of INR monitoring for the
nomogram were based on the American College of Chest
Physicians (ACCP) 2008 guidelines [22] as well as guide-
lines from the local anticoagulation clinic. The nomogram
was implemented within the renal program electronic
database. A copy of the nomogram is available from the
authors upon request. During the hemodialysis session, a
registered nurse would enter the patients’ current INR
level along with their current warfarin dose. The nomo-
gram would then instruct the nurse as to any potential
adjustments to the warfarin dose and/or frequency
required prior to the next INR measurement. The nomo-
gram was designed for maintenance of anticoagulation
therapy, and not for initiation of therapy. Patients initiat-
ing (or resuming) therapy had their warfarin dosing direc-
ted by a physician until their INR was therapeutic, at
which point they were eligible for maintenance therapy
following the warfarin nomogram. Time periods asso-
ciated with the initiation of anticoagulant therapy were
excluded from the study observation periods evaluating
effectiveness of the nomogram.
The warfarin nomogram was introduced in the outpa-
tient hemodialysis centers following in-servicing of the
nursing staff in January 2009. A one-month transition
period (February 2009) was included prior to evaluating
the nomogram.
Baseline Patient Data
Baseline demographic and laboratory data were collected
from the renal program electronic database [21] which
includes all patients undergoing hemodialysis in the
Southern Alberta Renal Program, including Calgary.
Baseline comorbidities, medications and dates of hospi-
talization were collected by a manual chart review of
both inpatient and outpatient medical records.
Outcome Data
The primary outcome was the proportion of INR mea-
surements within the indicated INR range (range INR ±
0.5 units). This range was chosen to facilitate comparison
of results to similar prior studies [23]. INR results for
patients for both periods were abstracted from the Renal
Program database. As the nomogram was developed for
maintenance of anticoagulation therapy, we excluded
time periods when warfarin was held or when patients
were admitted to hospital, plus a 2 week period following
re-initiation of warfarin or discharge from hospital. This
allowed for evaluation of maintenance of warfarin ther-
apy. Secondary outcomes included the mean number of
INR measurements per patient, number of bleeding and
thrombotic events and death, as determined by chart
review. Serious bleeding events were defined as clinically
overt bleeding resulting in death or hospitalization, a
drop in hemoglobin greater or equal to 2 g/dL or a
requirement for transfusion of 2 units of packed red
blood cells. Venous thrombosis was defined as pulmon-
ary embolus, lower or upper limb deep vein thrombosis,
cerebral sinus or venous thrombosis, or visceral vein
thrombosis.
Data Analysis
Patient demographic and clinical characteristics are pre-
sented as means and standard deviations or medians and
inter-quartile ranges for continuous variables, and per-
centages for categorical variables. Adequacy of anticoagu-
lation before and after implementation of the warfarin
nomogram was compared using generalized linear mixed
models, in order to account for correlation between
observations (patients may have been present in both
pre- and post-periods). A similar approach was used for
comparing the mean number of INR measurements for
the two time periods. The analysis of the proportion of
INR measurements within the range (± 0.5 units) was
stratified by range INR. All analyses were performed
using SAS version 9.2 (SAS Institute Inc, Cary, North
Carolina) and Stata version 10.1 (StataCorp, College
Station, Texas). A two-sided P value of < 0.05 was used
to indicate statistical significance. The institutional




A total of 67 patients were included in the pre-period
and 55 in the post-period, with 40 patients included in
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both periods. Patient demographic and clinical charac-
teristics were similar for the two periods (Table 1). The
majority of subjects were on warfarin for atrial fibrilla-
tion, and over 75% of subjects had a range INR of 2.0 to
3.0. Only 2 patients in the pre- and 3 patients in the
post-period had a range INR of 2.5 to 3.5.
Proportion of INR measurements within the range INR (±
0.5 units)
For range INR 1.5 to 2.5, the proportion of measure-
ments within range INR in the pre- (93.6% (95% CI:
88.6% - 96.5%)) and post- period (95.6% (95% CI: 89.4%
- 98.3%) (p = 0.95) were similar. Results were similar for
range INR 2.0 to 3.0, with 82.2% (95% CI: 77.9% -
85.8%) within range in the pre- and 77.4% (95% CI:
72.0% - 82.0%) within range in the post-period (p =
0.20). For range INR 2.5 to 3.5, a similar proportion of
INR within range in the pre- (84.3% (95% CI: 59.4% -
95.1%)) and the post- period (66.8% (95% CI: 39.9% -
86.0%)) (p = 0.29) was observed (Figure 1). Results were
similar in a sensitivity analysis restricted to the 40
patients in both the pre and post-periods.
Proportion of INR measurements precisely within the
range INR
The proportion of INR measurements that were pre-
cisely within the INR range showed similar results. For
range INR 1.5 to 2.5, a similar proportion of INR mea-
surements were within range in the pre-period (70.8%
(95% CI: 61.3% - 78.8%)) and the post-period (77.4%
(95% CI: 66.6% 85.5%)) (p = 0.67), while for range INR
2.0 to 3.0 the proportion within range were 51.5% (95%
CI: 46.2% - 56.7%) for the pre-period and 45.1% (95%
CI: 39.6% - 50.8%) for the post (p = 0.16). For range
INR 2.5 to 3.5, corresponding proportions were 62.1%
(95% CI: 37.3% - 81.9%) and 35.8% (95% CI: 18.3% -
58.2%) (p = 0.075) for pre- and post-period respectively
(Figure 2).
Number of INR measurements
The mean number of INR measurements per subject
decreased significantly following implementation of the





Age, mean (SD) 69.8 (12.8) 69.4 (14.0)
Male (%) 46 (68.7) 34 (61.8)
Diabetes (%) 34 (50.8) 33 (60.0)
Cause of end stage renal disease (%)
Diabetes Mellitus 24 (35.8) 23 (41.8)
Vascular 17 (25.4) 15 (27.3)
Glomerulonephritis 9 (13.4) 3 (5.5)
Other 9 (13.4) 8 (11.9)
Unknown 8 (11.9) 9 (16.4)
Indication for anticoagulation (%)
Thromboembolic disease 18 (26.9) 18 (32.7)
Cerebrovascular disease 1 (1.5) 1 (1.8)
Atrial fibrillation 31 (46.3) 23 (41.8)
Vascular access patency 4 (6.0) 2 (3.6)
Prosthetic valve 3 (4.5) 3 (5.5)
Unspecified or unknown 10 (14.9) 8 (14.6)
Range INR (%)
1.5 to 2.5 14 (20.9) 9 (16.4)
2.0 to 3.0 51 (76.1) 43 (78.2)
2.5 to 3.5 2 (3.0) 3 (5.5)
Prior bleed 11 (16.4) 11 (20.0)
Prior thromboembolic event 13 (19.4) 9 (16.4)
Known hereditary thrombotic disease 1 (1.5) 1 (1.8)
Use of Plavix 0 (0.0) 0 (0.0)
Use of NSAIDs or ASA 1 (1.5) 1 (1.8)
History of cancer 10 (14.9) 5 (9.1)
INR - International normalized ratio.
Figure 1 Proportion (95% CI) of INR measurements maintained
in range INR ± 0.5 by period and range INR.
Figure 2 Proportion (95% CI) of INR measurements maintained
in range INR by period and range INR.
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nomogram. During the pre-period there was a mean of
30.5 (95% confidence interval (CI) 27.0-34.0) measure-
ments per patient compared with 22.3 (95% CI 18.4-
26.1) in the post period (p = 0.0029). There were 3
bleeding events in each of the two periods. None of the
bleeding events occurred at a supra-therapeutic INR,
however, one of the bleeding events in the post-period
resulted in death (fall with cerebral bleed) and occurred
while the patient was off the nomogram, with an INR of
2.0. Overall, the number of deaths, irrespective of cause,
was similar in the two time periods with 7 (10.4%)
deaths occurring in the pre-period and 10 (18.2%) in the
post-period. Deaths in the pre-nomogram period largely
occurred out of hospital and thus were of unknown
cause (6/7, 85.7%) while deaths in the post-nomogram
were primarily in hospital (8/10, 80%) and for causes
other than bleeding or thrombosis related. There were
two thrombotic events in the pre-period (one in a
patient with active malignancy) and none in the post-
period.
Discussion
To our knowledge, this is the first study evaluating the
effectiveness of an electronic anticoagulation nomogram
to guide warfarin therapy in the out-patient hemodialysis
setting. We found that an electronic warfarin nomogram
administered by nurses achieved INR control similar to
that of physician directed therapy, although evidence of
efficacy remain to be determined in future studies. The
risk of bleeding and thrombotic events was also similar
for the two methods of warfarin administration.
A recent systematic review of outpatient anticoagula-
tion clinics reported that patients without end stage renal
disease (ESRD) are within range INR range approxi-
mately 64% of the time when managed by a pharmacist
or nurse guided anticoagulation nomogram [24]. How-
ever, given concerns about potential increased bleeding
risk in the ESRD population, these patients are often not
eligible for out-patient management of anticoagulation
from an anticoagulation clinic [5,6]. Results from our
study suggest that effectiveness of INR control was simi-
lar when managed by nurses using an electronic nomo-
gram, compared to physician directed ordering. This is
consistent with other non-physician directed anticoagula-
tion management in high risk patients with complicated
anticoagulation histories [23]. In hemodialysis patients,
anticoagulation therapy is often confounded by multiple
medications, significant comorbidity and burden of dis-
ease, nutritional deficiencies and altered pharmacoki-
netics due to the renal failure [25,26].
We found that the mean number of INR measurements
per patient decreased in the post-period, with similar
adequacy of INR control. The optimal frequency of
patient monitoring and intensity of oral anticoagulation
therapy is unclear. On the one hand, more frequent
monitoring is not only associated with greater cost and
inconvenience to the patient, but some patients with
more frequent testing spend less time within a therapeu-
tic INR, possibly due to frequent dose adjustments
[27-29]. However, patients with more comorbidities and
co-prescribed medications may have less stable pharma-
codynamics, in which case more frequent INR measure-
ments may be warranted [1,30,31].
Hemodialysis patients on anticoagulant therapy experi-
ence annual bleeding rates of 3.1% to 54% [6]. The annual
rates of bleeding in our study were lower than previous
systematic reviews published in this area, [6] and were
similar for both the physician-guided or nomogram
warfarin regime. Importantly the effectiveness of INR con-
trol and similar rates of bleeding in our study occurred
despite a significant reduction in the frequency of INR
testing. Use of the nomogram has the potential to enhance
care delivery and reduce cost by tailoring frequency of
repeat INR testing and allowing this aspect of care to be
delivered by a nurse rather than a physician.
There is controversy related to the use of warfarin in
hemodialysis patients given their increased bleeding
rates and risk of hemorrhagic stroked [6,32]. The poten-
tial benefit of anticoagulation for hemodialysis patients
that require anticoagulation on the basis of CHADS-2
or CHADS-VAS scoring systems remains uncertain, and
a randomized control trial will likely be required before
decisions regarding benefit and safety in this patient
population can be made.
Our study has limitations. It was conducted in a single
center, which may limit its generalizability. However, the
demographic characteristics of our population are similar
to the general Canadian hemodialysis population, [33]
thus it would be reasonable to assume our results are
also generalizable to other centers. The pre-post study
design is a further limitation, though we used appropriate
statistical technique to account for any potential correla-
tion from patients present in both time periods. There is
also potential for residual confounding in that we were
unable to account for factors such as diet, compliance
and new medications. Finally, the study size for the range
INR of 2.5 to 3.5 was too small to allow firm conclusions
to be drawn and any results should be interpreted with
caution in this subgroup of patients.
Conclusion
This study suggests that an electronic warfarin anticoagu-
lation nomogram administered by nurses was able to
achieve INR control similar to that of physician directed
therapy among hemodialysis patients, without an increase
in bleeding risk or thrombotic events. Use of the nomo-
gram also resulted in a significant reduction in the fre-
quency of INR testing. Evidence of the efficacy and safety
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of the nomogram remain to be determined in a controlled
trial design.
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